AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04852081
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Trial: NCT04852081
Drug: Exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
Trial: NCT04852081
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
Trial: NCT05378399
Drug: Descovy or Truvada
RxNorm normalized name: Descovy
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Descovy or Truvada prescribed with digital pills for PrEP
Trial: NCT05997238
Drug: without triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The preparation contains only the basic formula. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
Trial: NCT05997238
Drug: 20mg triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20mg triamcinolone was added to the preparation. Mix 20mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
Trial: NCT05997238
Drug: 40mg triamcinolone
RxNorm normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg triamcinolone was added to the preparation. Mix 40mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
Trial: NCT05997238
Drug: 80mg triamcinolone
RxNorm normalized name: triamcinolone acetonide 80 MG/ML
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg triamcinolone was added to the preparation. Mix 80mg triamcinolone and the basic formula to make a mixed preparation. The base formula contains 150mg ropivacaine and 0.5mg epinephrine. Add normal saline and mix to 80ml.
Trial: NCT05349058
Drug: Immune Checkpoint Inhibitors
RxNorm normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive Immune Checkpoint Inhibitor as per oncology protocol
Trial: NCT04863014
Drug: evinacumab
RxNorm normalized name: Evinacumab
DrugBank: Evinacumab (DB15354)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous infusion every 4 weeks (Q4W)
Trial: NCT01683110
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT05822908
Drug: VO659
RxNorm normalized name: VO659
DrugBank: VO659 (DB18160)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VO659 is an antisense oligonucleotide targeting CAG repeats in mRNA transcripts
Trial: NCT04873284
Drug: fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.~Fosaprepitant: 4 mg/kg IV
Trial: NCT04873284
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO. When used with aprepitant, dexamethasone dose was halved.~Oral aprepitant: D1：Powder for suspension 3.0 mg/kg (up to 125 mg),D2，D3：Powder for suspension 2.0 mg/kg (up to 80 mg).
Trial: NCT04873284
Drug: Granisetron plus dexamethasone
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.
Trial: NCT04810598
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral Tablet
Trial: NCT05876065
Drug: TPC
RxNorm normalized name: TPCA-1
DrugBank: TPCA-1 (DB17058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any physician's choice as maintenance therapy (except for XC regimen)
Trial: NCT02059694
Drug: Hyaluronidase
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT06043050
Drug: Platelets
RxNorm normalized name: HLA matched platelets
DrugBank: Lyophilized activated platelets (DB18369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational data: all platelet transfusions recorded in routine care medical file data.
Trial: NCT04831736
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine at a dose of 0.6 mg/kg will be administered intravenously (IV) while the participant is recovering in the PACU. The study drug will be administered over at least 30 minutes at one time point and will be administered after subject has been deemed to be stable (hemodynamically stable, awake) by the study team on POD 0.
Trial: NCT05498259
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib 150mg qd PO
Trial: NCT06503276
Drug: Orelabrutinib
RxNorm normalized name: Orelabrutinib
DrugBank: Orelabrutinib (DB16272)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orelabrutinib PO will be administered as per the schedule specified in the respective arm
Trial: NCT06530914
Drug: MRG003 combined with Pucotenlimab
RxNorm normalized name: miconazole
DrugBank: Pucotenlimab (DB17552)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Trial: NCT06530914
Drug: MRG003 combined with Pucotenlimab+Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.
Trial: NCT00000944
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000944
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00000944
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05607017
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken Orally
Trial: NCT04981665
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg IV Q3W
Trial: NCT04981665
Drug: TACE
RxNorm normalized name: Tace
DrugBank: Chlorotrianisene (DB00269)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TACE will be performed after curative resection (4±1w)
Trial: NCT05250596
Drug: Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.
Trial: NCT05250596
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.
Trial: NCT06053567
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On the target quit day (week 6), participants will be provided 8 weeks of nicotine replacement therapy (24-hour transdermal nicotine patches \[TNP\]).
Trial: NCT04916470
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
Trial: NCT06529952
Drug: hormonal treatment
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: using 3rd generation contraceptive pills
Trial: NCT05846516
Drug: VSV-GP154
RxNorm normalized name: Recombinant Vesicular Stomatitis Virus (rVSV) strain Indiana with a deletion of the VSV envelope glycoprotein (G) replaced with the Zaire Ebola Virus (ZEBOV) Kikwit 1995 strain surface glycoprotein (GP)
DrugBank: Ebola Zaire vaccine (live, attenuated) (DB15595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection
Trial: NCT05846516
Drug: Ezabenlimab
RxNorm normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT04974216
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration : IV at 12mg/Kg C1 to C3: D1, D8, D15, D22 C4 to C6: D1, D15 C7 to C12: D1
Trial: NCT04974216
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral administration: hard capsule C1 to C6: 20mg/day C7 to C12: 15mg/day
Trial: NCT04974216
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administration: IV at 375mg/m2 C1 to C6: D1
Trial: NCT05688904
Drug: Imipramine
RxNorm normalized name: Imipramine
DrugBank: Imipramine (DB00458)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 4% Imipramine
Trial: NCT04797247
Drug: lerodalcibep
RxNorm normalized name: Lerodalcibep
DrugBank: Lerodalcibep (DB19071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCSK9 inhibitor
Trial: NCT06193421
Drug: Ambroxol Hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg slow release (SR), X16/day or 300mg X4/day oral capsules.
Trial: NCT02755987
Drug: ANG1005
RxNorm normalized name: ANG1005
DrugBank: ANG1005 (DB18167)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06255223
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of multimodal radiotherapy, immunotherapy was given within 7 days and in a subsequent LDRT. The maximum duration is 24 months.
Trial: NCT02202473
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02202473
Drug: Lamivudine+Oxymatrine Capsules
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04290026
Drug: metoclopramide versus granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
Trial: NCT06454357
Drug: B007
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: B007：high dose/low dose: Subcutaneous injection was administered on days 1 and 15
Trial: NCT05006521
Drug: KN-002
RxNorm normalized name: KN-001
DrugBank: KN-001 (DB18495)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KN-002 dry powder inhaler
Trial: NCT05120934
Drug: Amitriptyline 25 MG
RxNorm normalized name: amitriptyline 25 MG
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg orally for 4 weeks
Trial: NCT05120934
Drug: Amitriptyline 50 MG
RxNorm normalized name: amitriptyline 50 mg oral tablet
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg orally for 4 weeks
Trial: NCT05120934
Drug: Duloxetine 30 MG
RxNorm normalized name: duloxetine 30 MG
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg orally for 4 weeks
Trial: NCT05120934
Drug: Duloxetine 60 MG
RxNorm normalized name: duloxetine 60 MG
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60mg orally for 4 weeks
Trial: NCT03363334
Drug: Fostamatinib disodium 100 mg
RxNorm normalized name: fostamatinib disodium 100 mg ORAL TABLET
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib Disodium tablet 100 mg PO bid (morning and evening)
Trial: NCT03363334
Drug: Fostamatinib disodium 150 mg
RxNorm normalized name: fostamatinib disodium 150 mg ORAL TABLET
DrugBank: Tamatinib (DB07159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fostamatinib Disodium tablet 150 mg PO bid (morning and evening)
Trial: NCT05483621
Drug: Beta-hCG
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of spermatogenesis
Trial: NCT05234684
Drug: Orelabrutinib + R-CHOP
RxNorm normalized name: pantolactone, (R)-
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The orelabrutinib is a white, round, uncoated tablet. The R-CHOP include rituximab, cyclophosphamide, doxorubicin, vincristine, and prednison.
Trial: NCT00325299
Drug: Magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05890118
Drug: Stelara
RxNorm normalized name: Stelara
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A commercial formulation of ustekinumab for SC control (0.5mg)
Trial: NCT06235216
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose of 10 mg/kg intravenously
Trial: NCT06173778
Drug: semaglutide 2.4mg
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached
Trial: NCT06173778
Drug: Nicotine Replacement Therapy (NRT, nicotine patch)
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.
Trial: NCT06308159
Drug: Vebeglogene autotemcel
RxNorm normalized name: betibeglogene autotemcel
DrugBank: Betibeglogene autotemcel (DB16900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.
Trial: NCT04398524
Drug: ISA101b
RxNorm normalized name: ISA101b
DrugBank: ISA101b (DB18694)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISA101b 4 times plus cemiplimab every 3 weeks for up to 24 months
Trial: NCT05918094
Drug: Experimental dose: modified XELOX + sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment option for the modified XELOX group (study group) is 200 mg of sintilimab IV Drip Q3W, 600 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 78 mg/m2 IV Drip Q3W.
Trial: NCT05918094
Drug: Standard dose: standard XELOX + sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment option for the standard XELOX group (control group) is 200 mg of sintilimab IV Drip Q3W, 1000 mg/m2 of capecitabine PO BID for day 1-14, and oxaliplatin 130 mg/m2 IV Drip Q3W.
Trial: NCT05942313
Drug: Buprenorphine/ Methadone exposure
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Validate candidate genes- and prenatal opioid exposure- related maternal relapse and NOWS outcome associations in pregnant women and their newborns.
Trial: NCT04851613
Drug: Afuresertib
RxNorm normalized name: Afuresertib
DrugBank: Afuresertib (DB11648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting doses of the combination therapy are afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1, 15 in the first cycle and afuresertib 125 mg PO, QD plus fulvestrant 500 mg IM, D1 Q4W in the subsequent cycles
Trial: NCT04851613
Drug: Afuresertib/placebo
DrugBank: Afuresertib (DB11648)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: afuresertib/placebo 125mg QD combined with fulvestrant 500mg Q4W (D1, 15 in cycle 1)
Trial: NCT05051566
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04980833
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant's treatment plan has been established by the treating physician, within the global compassionate use framework. Doses permitted are 50, 125, 200 and 250 mg.
Trial: NCT04829344
Drug: AG-920
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG-920 Sterile Topical Ophthalmic Solution
Trial: NCT04106999
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug infusion will be delivered intra-operatively
Trial: NCT06130059
Drug: Low Dose Colchicine
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine has been demonstrated to improve cardiovascular outcomes among patients with cardiovascular disease. In the COLCOT trial, the use of low-dose colchicine resulted in a reduction of major adverse cardiovascular events among participants with recent MI. The trial demonstrated the utility of anti-inflammatory therapies in improving cardiovascular outcomes. Colchicine has been widely used for decades and its safety profile is well established.
Trial: NCT04862143
Drug: Alpelisib
RxNorm normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
Trial: NCT04862143
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
Trial: NCT04862143
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
Trial: NCT06155968
Drug: PCA
RxNorm normalized name: PCA
DrugBank: Pidolic acid (DB03088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
Trial: NCT05997043
Drug: oral anti-Parkinson drugs and injection of botulinum toxin
RxNorm normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
Trial: NCT04826354
Drug: Rosuvastatin and Ezetimibe
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin Versus Rosuvastatin plus Ezetimibe
Trial: NCT05999955
Drug: Neomycin/ Dexameythasone/Xylometazoline
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The active-control in the phase II study was a commercial form of nasal spray containing Dexamethasone/Neomycin/Xylometazoline. This formulation is approved by Vietnam's Ministry of Health as a treatment regime for rhinosinusitis. Dexamethasone sodium phosphate is fluoromethyl prednisolone, a synthetic glucocorticoid. Dexamethasone has the main effects of glucocorticoids as anti-inflammatory, antiallergic and immunosuppressant. Neomycin sulfate is an antibiotic belonging to the group of aminoglycosides that have a bactericidal mechanism due to inhibition of bacterial protein biosynthesis. In this study, the nasal spray is used as an adjunct to Amoxicillin/Clavulanate standard treatment
Trial: NCT02176135
Drug: Auranofin
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 mg tablets
Trial: NCT05233228
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Provision of nicotine replacement medications in the form of transdermal patches is important to address nicotine withdrawal/craving for smokers who want to quit. Evidence supporting the safety and efficacy of NRT is vast. The PHS Guideline indicates that use of NRT doubles quit rates and should be considered the minimal standard care. Therefore, we will provide NRT to all participants in both groups in the early cessation phase.